Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 14, 2018

View Archived Issues

Microenvironment trouble underlies chemo brain

Antiviral response damages kidney in bacterial sepsis

New pyrrolidine sulfonamides as TRPV4 antagonists

DNA-encoded monoclonal antibody targeting PCSK9 reduces LDL cholesterol in mice

Preliminary results presented from first-in-human study of ACTR-707 in combination with rituximab

Vecabrutinib shows preliminary evidence of activity in advanced B-cell malignancies

Bristol-Myers Squibb presents phase Ib/II data for ulocuplumab in multiple myeloma

Higher toxicity and lower adherence for alternative palbociclib dosing schedule in breast cancer

BAT-8003, a novel anti-Trop-2 ADC with promising activity in TNBC mouse models

OncoSec reports updated tumor response data for KEYNOTE-695 study

Lilly and AC Immune enter agreement to research and develop tau aggregation inhibitors

Rodin Therapeutics initiates phase I study of RDN-929

GARDP to screen libraries from Eisai and Takeda for new antibiotics

OBI Pharma opens phase III trial of adagloxad simolenin and OBI-821 for high-risk early-stage TNBC

Virginia Tech collaborates with NIH to study ML-351 for chronic pain

Mutation in orexin receptor is associated with panic disorder development and response to therapy

Targeting alpha-synuclein can mitigate stroke damage

Czech Academy of Sciences institutes patent PGE2 production inhibitors

Cancer Research Technology discovers BCL-6 inhibitors

Ono Pharmaceutical identifies new prostanoid EP4 receptor antagonists

Chinese researchers divulge RORC antagonists

Protagonist begins phase I study of PN-10943 for inflammatory bowel disease

Seliforant shown not to affect vigilance, cognitive performance during motion stimulus

Phase I primary endpoint met in phase I/II study of NC-6300

Rhythm begins phase III trial of setmelanotide in Bardet-Biedl syndrome and Alstrom syndrome

Aptevo initiates phase I/Ib study of APVO-436 for AML and MDS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...